Torskal Overview
- Year Founded
-
2015
- Status
-
Private
- Employees
-
3
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$2.22M
- Investors
-
5
Torskal General Information
Description
Operator of a biotech company intended to design disruptive gold nanoparticles for cancer therapy using green chemistry. The company uses green nanotechnology for the development of non-toxic and eco-friendly nanomaterials for the treatment of surface and deep cancers, enabling healthcare providers to cure their patients with non-toxic, and eco-friendly cancer therapies that target both surface and deep cancers that promotes treatment outcomes while reducing harmful side effects.
Contact Information
Website
www.torskal.comCorporate Office
- 2 rue Maxime Rivière
- Sainte Clotilde
- 97490
- France
Corporate Office
- 2 rue Maxime Rivière
- Sainte Clotilde
- 97490
- France
Torskal Timeline
Torskal Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Later Stage VC | 02-Feb-2026 | $2.22M | Completed | Pre-Clinical Trials | ||
| 7. Seed Round | 13-Feb-2025 | Completed | Pre-Clinical Trials | |||
| 6. Seed Round | 31-Dec-2020 | Completed | Pre-Clinical Trials | |||
| 5. Accelerator/Incubator | 23-Jun-2017 | Completed | Clinical Trials - Phase 1 | |||
| 4. Grant | 31-Dec-2016 | Completed | Clinical Trials - Phase 1 | |||
| 3. Grant | Completed | Clinical Trials - Phase 1 | ||||
| 2. Accelerator/Incubator | Completed | Clinical Trials - Phase 1 | ||||
| 1. Accelerator/Incubator | Completed | Clinical Trials - Phase 1 |
Torskal Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | ||||||||
| Ordinary Shares | ||||||||
| Ordinary Shares | ||||||||
| Ordinary Shares | 123 | $82.157535 | $714.5 | $714.5 | 1x | $714.5 | 1.07% | |
| Ordinary Shares | 399 | $82.157535 | $664.3 | $664.3 | 1x | $664.3 | 3.48% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Torskal Comparisons
Industry
Financing
Details
Torskal Competitors (2)
One of Torskal’s 2 competitors is Nanospectra, a Venture Capital-Backed company based in Houston, TX.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Nanospectra | Venture Capital-Backed | Houston, TX | ||||
| Nanobiotix | Formerly VC-backed | Paris, France |
Torskal Patents
Torskal Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| FR-3164393-A1 | Plasmon photothermal treatment of skin cancers with extensive lesions using gold nanoparticles | Pending | 10-Jul-2024 | ||
| FR-3131850-A1 | Ultrasonic-assisted synthesis of nanoparticles consisting of a gold-covered ferric core | Active | 20-Jan-2022 | ||
| FR-3131850-B1 | Ultrasound-assisted synthesis of nanoparticles consisting of a gold-coated ferric core | Inactive | 20-Jan-2022 | ||
| WO-2022263451-A1 | Peptides derived from the spike protein of sars-cov-2 and uses thereof for diagnosis and vaccine purposes | Inactive | 15-Jun-2021 | ||
| EP-4313445-A1 | Ecologic method for preparing silver nanoparticles from an extract of and uses thereof | Inactive | 26-Mar-2021 | B22F9/24 |
Torskal Signals
Torskal Investors (5)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Clinifutur | Corporation | Minority | ||
| Silicon Valley Advantage | Accelerator/Incubator | |||
| European Commission | Government | |||
| Matwin | Accelerator/Incubator | |||
| The Technopole of Reunion Island | Accelerator/Incubator |
Torskal FAQs
-
When was Torskal founded?
Torskal was founded in 2015.
-
Where is Torskal headquartered?
Torskal is headquartered in France.
-
What is the size of Torskal?
Torskal has 3 total employees.
-
What industry is Torskal in?
Torskal’s primary industry is Specialty Chemicals.
-
Is Torskal a private or public company?
Torskal is a Private company.
-
What is the current valuation of Torskal?
The current valuation of Torskal is .
-
What is Torskal’s current revenue?
The current revenue for Torskal is .
-
How much funding has Torskal raised over time?
Torskal has raised $2.79M.
-
Who are Torskal’s investors?
Clinifutur, Silicon Valley Advantage, European Commission, Matwin, and The Technopole of Reunion Island have invested in Torskal.
-
Who are Torskal’s competitors?
Nanospectra and Nanobiotix are competitors of Torskal.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process